thanks jess: amazinger and amazinger. "...Therefore, these results indicate that r84 may be more effective at controlling tumor take and growth than bevacizumab independent of dose in certain models. We propose that the appropriate therapeutic antibody dose should be determined independently for different tumor types to maximize therapeutic benefit with minimal induction of toxicity [23–25]." Truly stuff worth reading. Great paper. congrats to all involved.